BCL2 and neoplasm: Numerous studies have demonstrated that cetuximab treatment can reduce tumour survival through a number of mechanisms, including downregulating angiogenic factors and matrix metalloproteinases that are involved in cell adhesion to lessen cancer cell metastasis, upregulating Bax and other proapoptotic factors, downregulating Bcl2 and activating caspases, and inducing ADCC in vivo by attracting immune cells to tumour cells 5.